Loss of syk kinase during IgE-mediated stimulation of human basophils

Donald Macglashan, Katsushi Miura

Research output: Contribution to journalArticle

Abstract

Ongoing secretion from human basophils is a balance of activation and deactivation events. Recent studies have focused on downregulatory steps that appear to modify the presence of the activated state of various signaling molecules. We now examine downregulation regulated by mechanisms related to proteasome processing. To determine the long-term effects of FcεRI aggregation on expression of syk kinase. Peripheral blood basophils were examined for changes in the expression of syk kinase after stimulation with optimal and suboptimal stimulation. Stimulation results in a 20% loss of syk in 1 hour and an 80% loss of syk in longer incubations (>18 hours). Loss of syk in this time frame can occur at levels of stimulation that do not result in observable mediator release. Loss of syk occurs after stimulation with either anti-IgE antibody or antigen. Activation is shown to result in c-Cbl phosphorylation, and its association with syk and immunoblotting reveals the appearance of a ladder of syk species with molecular weights that are consistent with ubiquitylation of syk. Stimulation in the presence of a proteasome inhibitor such as lactacystin A results in the sustained presence of very high-molecular-weight ubiquitylated species, although it does not alter the presence of the syk ladder. Although the loss of syk is probably too slow to account for downregulation of ongoing secretion of histamine or leukotriene C4 release, it may lead to longer-term alterations in basophil function that explain characteristics of clinical procedures like rapid drug desensitization.

Original languageEnglish (US)
Pages (from-to)1317-1324
Number of pages8
JournalThe Journal of Allergy and Clinical Immunology
Volume114
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

Basophils
Immunoglobulin E
Down-Regulation
Molecular Weight
Leukotriene C4
Proteasome Inhibitors
Ubiquitination
Proteasome Endopeptidase Complex
Immunoblotting
Histamine
Phosphorylation
Antigens
Pharmaceutical Preparations
Syk Kinase

Keywords

  • desensitization
  • kinases
  • Mast cells/basophils
  • secretion
  • signal transduction

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Loss of syk kinase during IgE-mediated stimulation of human basophils. / Macglashan, Donald; Miura, Katsushi.

In: The Journal of Allergy and Clinical Immunology, Vol. 114, No. 6, 12.2004, p. 1317-1324.

Research output: Contribution to journalArticle

@article{3813cf3a7ff24342962664238f2b04b5,
title = "Loss of syk kinase during IgE-mediated stimulation of human basophils",
abstract = "Ongoing secretion from human basophils is a balance of activation and deactivation events. Recent studies have focused on downregulatory steps that appear to modify the presence of the activated state of various signaling molecules. We now examine downregulation regulated by mechanisms related to proteasome processing. To determine the long-term effects of FcεRI aggregation on expression of syk kinase. Peripheral blood basophils were examined for changes in the expression of syk kinase after stimulation with optimal and suboptimal stimulation. Stimulation results in a 20{\%} loss of syk in 1 hour and an 80{\%} loss of syk in longer incubations (>18 hours). Loss of syk in this time frame can occur at levels of stimulation that do not result in observable mediator release. Loss of syk occurs after stimulation with either anti-IgE antibody or antigen. Activation is shown to result in c-Cbl phosphorylation, and its association with syk and immunoblotting reveals the appearance of a ladder of syk species with molecular weights that are consistent with ubiquitylation of syk. Stimulation in the presence of a proteasome inhibitor such as lactacystin A results in the sustained presence of very high-molecular-weight ubiquitylated species, although it does not alter the presence of the syk ladder. Although the loss of syk is probably too slow to account for downregulation of ongoing secretion of histamine or leukotriene C4 release, it may lead to longer-term alterations in basophil function that explain characteristics of clinical procedures like rapid drug desensitization.",
keywords = "desensitization, kinases, Mast cells/basophils, secretion, signal transduction",
author = "Donald Macglashan and Katsushi Miura",
year = "2004",
month = "12",
doi = "10.1016/j.jaci.2004.08.037",
language = "English (US)",
volume = "114",
pages = "1317--1324",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Loss of syk kinase during IgE-mediated stimulation of human basophils

AU - Macglashan, Donald

AU - Miura, Katsushi

PY - 2004/12

Y1 - 2004/12

N2 - Ongoing secretion from human basophils is a balance of activation and deactivation events. Recent studies have focused on downregulatory steps that appear to modify the presence of the activated state of various signaling molecules. We now examine downregulation regulated by mechanisms related to proteasome processing. To determine the long-term effects of FcεRI aggregation on expression of syk kinase. Peripheral blood basophils were examined for changes in the expression of syk kinase after stimulation with optimal and suboptimal stimulation. Stimulation results in a 20% loss of syk in 1 hour and an 80% loss of syk in longer incubations (>18 hours). Loss of syk in this time frame can occur at levels of stimulation that do not result in observable mediator release. Loss of syk occurs after stimulation with either anti-IgE antibody or antigen. Activation is shown to result in c-Cbl phosphorylation, and its association with syk and immunoblotting reveals the appearance of a ladder of syk species with molecular weights that are consistent with ubiquitylation of syk. Stimulation in the presence of a proteasome inhibitor such as lactacystin A results in the sustained presence of very high-molecular-weight ubiquitylated species, although it does not alter the presence of the syk ladder. Although the loss of syk is probably too slow to account for downregulation of ongoing secretion of histamine or leukotriene C4 release, it may lead to longer-term alterations in basophil function that explain characteristics of clinical procedures like rapid drug desensitization.

AB - Ongoing secretion from human basophils is a balance of activation and deactivation events. Recent studies have focused on downregulatory steps that appear to modify the presence of the activated state of various signaling molecules. We now examine downregulation regulated by mechanisms related to proteasome processing. To determine the long-term effects of FcεRI aggregation on expression of syk kinase. Peripheral blood basophils were examined for changes in the expression of syk kinase after stimulation with optimal and suboptimal stimulation. Stimulation results in a 20% loss of syk in 1 hour and an 80% loss of syk in longer incubations (>18 hours). Loss of syk in this time frame can occur at levels of stimulation that do not result in observable mediator release. Loss of syk occurs after stimulation with either anti-IgE antibody or antigen. Activation is shown to result in c-Cbl phosphorylation, and its association with syk and immunoblotting reveals the appearance of a ladder of syk species with molecular weights that are consistent with ubiquitylation of syk. Stimulation in the presence of a proteasome inhibitor such as lactacystin A results in the sustained presence of very high-molecular-weight ubiquitylated species, although it does not alter the presence of the syk ladder. Although the loss of syk is probably too slow to account for downregulation of ongoing secretion of histamine or leukotriene C4 release, it may lead to longer-term alterations in basophil function that explain characteristics of clinical procedures like rapid drug desensitization.

KW - desensitization

KW - kinases

KW - Mast cells/basophils

KW - secretion

KW - signal transduction

UR - http://www.scopus.com/inward/record.url?scp=9644287858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644287858&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2004.08.037

DO - 10.1016/j.jaci.2004.08.037

M3 - Article

C2 - 15577829

AN - SCOPUS:9644287858

VL - 114

SP - 1317

EP - 1324

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -